BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation

BACKGROUND: Mutated epidermal growth factor receptor (EGFR) is one of the most successful targets in cancer targeted therapy. While this treatment has benefited many patients with an activating EGFR mutation (EGFRm), almost all those who initially benefited will eventually develop acquired drug resi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Biosci
Autors principals: Zhan, Yihong, Wang, Yue, Qi, Miao, Liang, Panpan, Ma, Yu, Li, Ting, Li, Hui, Dai, Congmei, An, Zhifeng, Qi, Yitao, Wu, Hongmei, Shao, Huanjie
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6651933/
https://ncbi.nlm.nih.gov/pubmed/31367332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13578-019-0322-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars